SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Comparative effectiveness of total laryngectomy versus organ preservation in T3 laryngeal cancer: a systematic review and meta-analysis.
Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concurrent chemoradiotherapy vs. total laryngectomy in locally advanced laryngeal squamous cell carcinoma: a propensity score-matched retrospective cohort study.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of T3 laryngeal cancer involves balancing disease control and preserving laryngeal function. Studies show comparable survival outcomes between total laryngectomy (TL) and organ-preserving therapy (OPT), such as radiotherapy (RT) and chemoradiotherapy (CRT). However, OPT is suitable for only a subset of patients, and its protocols vary by institution. While OPT offers functional benefits, TL is associated with reduced risk of recurrence. In this review, we compare both TL and OPT in terms of locoregional control, salvage rates, and survival rates.
methodsWe searched PubMed, Scopus, Web of Science, and the Cochrane Library for relevant articles up to February 2025. Two independent reviewers extracted data from the selected studies, including baseline information, outcomes, complications, and survival rates.
resultsThirty-seven articles were eligible for inclusion in our review. Local recurrence in TL was notably less than that seen with OPT, whereas CRT and RT demonstrated fewer regional relapses compared to TL. OPT patients who experienced recurrence often required a salvage of TL; most of those received RT alone as the primary treatment. For TL, the 5-year DFS was 60%, the 5-year DSS was 66%, and the 5-year OS was 54%, as opposed to 53%, 61%, and 49% for OPT (p = 0.0087, p = 0.0094, p < 0.0001). Common complications with total laryngectomy included pharyngocutaneous fistulas, whereas OPT was associated with post-radiation laryngeal edema and esophageal strictures. Treatment-related mortality was reported similarly for both modalities.
conclusionTL offers superior survival outcomes (DFS, DSS, OS) over OPT for T3 laryngeal cancer, with higher cancer-free survival rates at one and five years. While total laryngectomy was associated with statistically higher survival outcomes, the absolute differences were modest. These findings support careful, individualized treatment selection that incorporates patient preference, functional outcomes, and institutional expertise.
Indexed as
Identifiers
41329200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.